Mirum Pharmaceuticals (MIRM) EBIAT (2020 - 2025)
Mirum Pharmaceuticals (MIRM) has 6 years of EBIAT data on record, last reported at -$5.7 million in Q4 2025.
- For Q4 2025, EBIAT rose 75.91% year-over-year to -$5.7 million; the TTM value through Dec 2025 reached -$23.4 million, up 73.43%, while the annual FY2025 figure was -$23.4 million, 73.43% up from the prior year.
- EBIAT reached -$5.7 million in Q4 2025 per MIRM's latest filing, down from $2.9 million in the prior quarter.
- Across five years, EBIAT topped out at $57.5 million in Q4 2021 and bottomed at -$74.0 million in Q2 2023.
- Average EBIAT over 5 years is -$24.7 million, with a median of -$26.1 million recorded in 2022.
- Peak YoY movement for EBIAT: skyrocketed 254.68% in 2021, then crashed 175.01% in 2023.
- A 5-year view of EBIAT shows it stood at $57.5 million in 2021, then plummeted by 163.31% to -$36.4 million in 2022, then increased by 2.12% to -$35.7 million in 2023, then surged by 33.28% to -$23.8 million in 2024, then soared by 75.91% to -$5.7 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$5.7 million in Q4 2025, $2.9 million in Q3 2025, and -$5.9 million in Q2 2025.